Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development

SEOUL - South Korean biotech Celltrion plans on speeding up development of its biosimilars by selling a 10 percent stake in the company to Singapore's Ion Investments B.V., a wholly-owned subsidiary of Temasek Holdings